keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/28225439/tachycardia-in-patients-treated-with-clozapine-versus-antipsychotic-long-acting-injections
#1
Björn M Nilsson, Oscar Edström, Leif Lindström, Petter Wernegren, Robert Bodén
Tachycardia is a known adverse effect during clozapine treatment. However, prevalence reported differs widely between studies and hitherto there are no studies comparing clozapine-treated patients with a similar control group. The present study was carried out to assess the prevalence of tachycardia in patients treated with clozapine and antipsychotic long-acting injections (LAI). Data on heart rate (HR), concomitant medication, and relevant anthropometric and laboratory measurements were collected for all clozapine-treated patients (n=174) in a defined catchment area and compared with data on patients treated with LAI (n=87)...
February 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28195930/treatment-duration-with-long-acting-injectable-antipsychotics-after-in-hospital-initiation-a-retrospective-cohort-study
#2
Hans Rittmannsberger, Jan Rosenleitner, Gertraud Malsiner-Walli, Regina Werl, Barbara Rittmannsberger, Kurosch Yazdi
PURPOSE: Long-acting injectable (LAI) antipsychotics are recommended especially for patients with multiple admissions and poor adherence. The empirical basis of this strategy is a matter of debate. METHODS: In a retrospective cohort study extending over 6 years, all patients admitted for inpatient treatment with a diagnosis of psychotic disorders according to International Statistical Classification of Diseases and Related Health Problems, 10th Revision (F2) were screened for treatment episodes with a new start of an LAI...
February 13, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28181959/indications-for-and-use-of-long-acting-injectable-antipsychotics-consideration-from-an-inpatient-setting
#3
Taishiro Kishimoto, Sohag Sanghani, Mark J Russ, Akeem N Marsh, Joshua Morris, Suparna Basu, Majnu John, John M Kane
Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed...
February 8, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28177063/prevalence-of-and-factors-associated-with-antipsychotic-polypharmacy-in-patients-with-serious-mental-illness-findings-from-a-cross-sectional-study-in-an-upper-middle-income-country
#4
Kerryn S Armstrong, Henk Temmingh
Objective: The aim of our study was to examine the prevalence of and factors associated with antipsychotic polypharmacy (APP) among patients with serious mental illness in the current South African health care context. Methods: We collected data on patient, illness, and treatment characteristics of patients discharged on one or more antipsychotic agents from January to June 2014. We analyzed the associations of APP with demographic and clinical variables using hierarchical multivariable logistic regression, and examined prescription patterns...
February 6, 2017: Revista Brasileira de Psiquiatria
https://www.readbyqxmd.com/read/28146613/efficacy-and-safety-of-aripiprazole-once-monthly-in-the-maintenance-treatment-of-bipolar-i-disorder-a-double-blind-placebo-controlled-52-week-randomized-withdrawal-study
#5
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Phyllis M Salzman, Robert D McQuade, Margaretta Nyilas, William H Carson
OBJECTIVE: To evaluate efficacy, safety, and tolerability of long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) as maintenance treatment for bipolar I disorder (BP-I). METHODS: In a double-blind, placebo-controlled, 52-week randomized withdrawal study conducted from August 2012 to April 2016, patients with a DSM-IV-TR diagnosis of BP-I currently experiencing a manic episode were stabilized sequentially on oral aripiprazole and AOM 400 and then randomized to AOM 400 or placebo...
January 31, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28145912/possible-opioid-shopping-and-its-correlates
#6
Alexander M Walker, Lisa B Weatherby, M Soledad Cepeda, Daniel Bradford, Yingli Yuan
BACKGROUND: We created an operational definition of possible opioid shopping in US commercial health insurance data and examined its correlates. METHODS: The population consisted of 264,204 treatment courses in persons with a fill for an opioid or diuretic prescription in 2012 and a second within 18 months. We examined counts of prescribers and pharmacies and the numbers of fills and overlaps for ability to discriminate courses of opioids from diuretics, which were a negative control...
January 31, 2017: Clinical Journal of Pain
https://www.readbyqxmd.com/read/28144147/neuroleptic-malignant-syndrome-an-easily-overlooked-neurologic-emergency
#7
REVIEW
Ramadhan Oruch, Ian F Pryme, Bernt A Engelsen, Anders Lund
Neuroleptic malignant syndrome is an unpredictable iatrogenic neurologic emergency condition, mainly arising as an idiosyncratic reaction to antipsychotic agent use. It is characterized by distinctive clinical features including a change in mental status, generalized rigidity, hyperpyrexia, and dysautonomia. It can be lethal if not diagnosed and treated properly. Mortality and morbidity attributed to this syndrome have recently declined markedly due to greater awareness, earlier diagnosis, and intensive care intervention...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28140680/paliperidone-for-the-treatment-of-schizophrenia-and-schizoaffective-disorders-a-drug-safety-evaluation
#8
M C Mauri, A Reggiori, S Paletta, C Di Pace, A C Altamura
Paliperidone, the major active metabolite of risperidone, is a second-generation antipsychotic that has been developed as an extended-release (ER) oral formulation and a long-acting injectable paliperidone palmitate (PP) formulation. Paliperidone has demonstrated efficacy in the reduction of acute schizophrenia symptoms and clinical benefits were maintained also in the long-term treatments. Paliperidone ER and PP are generally well tolerated with a predictable adverse event profile. Areas covered: Data from studies evaluating safety and tolerability in the acute and maintenance treatment of schizophrenia with paliperidone are reviewed...
March 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28139358/clozapine-and-long-acting-injectable-antipsychotic-combination-a-retrospective-one-year-mirror-image-study
#9
Lama Souaiby, Claire Gauthier, Christine Rieu, Marie-Odile Krebs, Emmanuelle Advenier-Iakovlev, Raphaël Gaillard
To evaluate efficacy and tolerability of the combination of clozapine with an antipsychotic long-acting injectable (LAI) in multi-episode patients with schizophrenia or schizoaffective disorder. Efficacy and tolerability were assessed in seventeen patients admitted to a hospital in Paris between January 2010 and June 2015, using a one-year mirror-image design. Number and length of hospitalizations significantly decreased after introducing the combination (2.1 vs 0.8, p=0.004 and 155.4days vs 26.6days, p<0...
January 27, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28119036/one-year-mirror-image-study-using-paliperidone-palmitate-for-relapse-prevention-of-schizophrenia-in-four-university-hospitals-in-canada
#10
Philippe D Vincent, Marie-France Demers, Venessa Doyon-Kemp, Josée Duchesneau, Alex Halme, Violaine Masson
BACKGROUND: Superiority of long acting injectable antipsychotics (LAI) over oral antipsychotics remains controversial and dependent on study design and inclusion criteria. Meta-analysis of 21 RCTs demonstrated no difference in their effectiveness, but meta-analysis of 25 mirror-image studies did. None of these included paliperidone palmitate (PP). METHODS: We challenged efficiency of PP in a multicentric mirror-image study. Primary outcome was total hospitalization days...
January 21, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28112539/long-acting-injectable-antipsychotics-in-children-and-adolescents
#11
Sarah Lytle, Molly McVoy, Martha Sajatovic
OBJECTIVE: While a number of articles have reviewed the use of long-acting injectable antipsychotics (LAIs) in first-episode psychosis, there has been extremely limited focus on LAIs in children and adolescents. This review of the literature evaluated use of LAIs in children and youth under the age of 18. METHODS: We conducted a comprehensive search of the PubMed, PsychINFO, CINAHL, and EMBASE databases using keywords related to LAIs, children, and psychiatric conditions, including schizophrenia, bipolar disorder, and schizoaffective disorder...
February 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28080146/perceptions-vs-evidence-therapeutic-substitutes-for-antipsychotics-in-patients-with-dementia-in-long-term-care
#12
Brianne L Olivieri-Mui, John W Devlin, Aileen Ochoa, Danielle Schenck, Becky Briesacher
OBJECTIVE: To compare differences between clinician perceptions of therapeutic substitutes for antipsychotics prescribed to patients with dementia in long term care (LTC) and published evidence. METHODS: A mixed-methods approach that included a drug information search, online survey of 55 LTC clinicians and a comprehensive literature review was used. For 41 pharmacologic antipsychotic substitute candidates identified, LTC clinicians rated the likelihood they would substitute each for patients with dementia and identified non-pharmacologic antipsychotic substitutes...
January 12, 2017: Aging & Mental Health
https://www.readbyqxmd.com/read/28055336/treatment-persistence-and-hospitalization-rates-among-patients-with-schizophrenia-a-quasi-experiment-to-evaluate-a-patient-information-program
#13
Dominic Pilon, Tony B Amos, Guillaume Germain, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela J Benson
OBJECTIVE: The effective treatment of schizophrenia requires continuous antipsychotic maintenance therapy. However, poor persistence of treatment is common among patients with schizophrenia. The objective of this study was to compare persistence and hospitalization rates among patients with schizophrenia treated with long-acting injectable (LAI) antipsychotics (i.e., paliperidone palmitate and risperidone) and enrolled in a patient information program (program cohort) with patients treated with oral antipsychotics (OAs) who were not enrolled in a patient information program (nonprogram cohort)...
January 5, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28044942/emerging-pharmacological-therapies-in-schizophrenia-what-s-new-what-s-different-what-s-next
#14
Leslie Citrome
There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28005578/paliperidone-palmitate-once-monthly-treatment-in-recent-onset-and-chronic-illness-patients-with-schizoaffective-disorder
#15
Cynthia A Bossie, Ibrahim Turkoz, Larry Alphs, Lucy Mahalchick, Dong-Jing Fu
Data from a multiphase schizoaffective disorder study (NCT01193153) were used to examine the effects of paliperidone palmitate once-monthly (PP1M) by subjects' illness duration, defined as recent onset (≤5 years since first psychiatric diagnosis; n = 206) and chronic illness (>5 years; n = 461). Symptom and functioning scores, as measured during open-label PP1M acute and stabilization treatment phases, improved in both subpopulations, with greater improvements in recent onset than chronic illness subjects (p ≤ 0...
December 21, 2016: Journal of Nervous and Mental Disease
https://www.readbyqxmd.com/read/28004623/new-ema-report-on-paliperidone-3-month-injections-taking-clinical-and-policy-decisions-without-an-adequate-evidence-base
#16
G Ostuzzi, D Papola, C Gastaldon, C Barbui
Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (EMA) in a public assessment report, released in April 2016. In this commentary, the main strengths and limitations of the EMA assessment report were appraised and discussed, in order to highlight possible implications for clinical practice, future research and regulatory practices for drug approval...
December 22, 2016: Epidemiology and Psychiatric Sciences
https://www.readbyqxmd.com/read/27994714/factors-associated-with-adherence-to-the-hedis-quality-measure-in-medicaid-patients-with-schizophrenia
#17
Marie-Hélène Lafeuille, Christian Frois, Michel Cloutier, Mei Sheng Duh, Patrick Lefebvre, Jacqueline Pesa, Zoe Clancy, John Fastenau, Mike Durkin
BACKGROUND: Treatment continuity is a major challenge in the long-term management of patients with schizophrenia; poor patient adherence to antipsychotic drugs has been associated with negative clinical outcomes. Long-acting injectable therapies may improve adherence and lessen the risk for psychiatric-related relapse, often leading to rehospitalization and higher healthcare costs. Therefore, understanding the determinants of adherence to antipsychotics is critical in the management of patients with schizophrenia...
October 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27979642/severe-carisoprodol-withdrawal-after-a-14-year-addiction-and-acute-overdose
#18
Kathy T Vo, Howard Horng, Craig G Smollin, Neal L Benowitz
BACKGROUND: Carisoprodol, a centrally acting muscle relaxant with a high abuse potential, has barbiturate-like properties at the GABA-A receptor, leading to central nervous system depression and desired effects. Its tolerance and dependence has been previously demonstrated in an animal model, and withdrawal has been described in several recent case reports. Many cases can be effectively managed with a short course of benzodiazepines or antipsychotic agents. However, abrupt cessation in a patient with a history of long-term and high-dose carisoprodol abuse may result in symptoms that are more difficult for providers to treat...
December 12, 2016: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/27971818/impact-of-initiation-of-long-acting-injectable-antipsychotics-on-resource-utilization-in-patients-with-schizophrenia
#19
J Lachaine, M Larbi, P Melnyk, A Rouleau, V Baribeau, E Stip
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971420/retrospective-database-study-describing-patient-characteristics-and-resource-use-in-swedish-patients-receiving-second-generation-long-acting-injection-antipsychotics
#20
E Hernlund, E Landfeldt, L A Lombard, A Tockhorn-Heidenreich, C Bushe, V Porsdal, J Eriksson, J Berg
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"